Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Intravenous immunoglobulin treatment following the first demyelinating event suggestive of multiple sclerosis: A randomized, double-blind, placebo-controlled trial

Neurological and clinical assessments were done every three months, and brain magnetic resonance imaging was performed at baseline and the end of the study (one year).The cumulative probability of developing clinically definite multiple sclerosis was significantly lower in the IVIg treatment group c...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:American journal of ophthalmology 2005-03, Vol.139 (3), p.582-582
Hauptverfasser: Achiron, A., Kishner, I., Sarova-Pinhas, I., Raz, H., Faibel, M., Stern, Y., Lavie, M., Gurevich, M., Dolev, M., Magalashvili, D., Barak, Y.
Format: Artikel
Sprache:eng
Schlagworte:
Confidence intervals
Drug therapy
Multiple sclerosis
NMR
Nuclear magnetic resonance
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Neurological and clinical assessments were done every three months, and brain magnetic resonance imaging was performed at baseline and the end of the study (one year).The cumulative probability of developing clinically definite multiple sclerosis was significantly lower in the IVIg treatment group compared with the placebo group (rate ratio, 0.36 [95% confidence interval, 0.15-0.88]; P = .03).
ISSN:0002-9394
1879-1891
DOI:10.1016/j.ajo.2004.12.093